Novartis announced that an interim analysis of a pivotal phase III study showed Afinitor (everolimus) tablets in combination with exemestane significantly extended Progression-Free Survival (PFS), or time without tumour growth, when compared to placebo plus exemestane in women with advanced breast cancer. The trial was stopped early after interim results showed the primary endpoint of PFS was met. The study included postmenopausal women with ER+HER2- metastatic breast cancer whose disease has progressed, despite initial endocrine therapy.
“Despite clinical progress in advanced breast cancer, most women are either initially resistant or develop resistance to endocrine therapy over time. As a result, there is a significant need for new treatment options,” said Hervé Hoppenot, president, Novartis Oncology. “Based on these study results, this combination has the potential to extend the time until chemotherapy is needed for these patients.”
The study, BOLERO-2 (Breast cancer trials of OraL EveROlimus-2), is a phase III, randomized, double-blind, placebo-controlled study of everolimus in combination with exemestane versus placebo plus exemestane in postmenopausal women with estrogen receptor-positive locally-advanced or metastatic breast cancer, whose disease has progressed, despite treatment with the nonsteroidal aromatase inhibitors letrozole or anastrozole.
Results will be presented at an upcoming medical conference and worldwide regulatory submissions are being planned by the end of 2011.
Everolimus targets mTOR in cancer cells, a protein that acts as an important regulator of tumour cell division, blood vessel growth and cell metabolism. Everolimus is also being investigated for the treatment of patients with HER2+ advanced breast cancer.
BOLERO-2 involved more than 700 patients at over 195 sites worldwide. Patients in the trial were randomized (2:1) to receive continuous therapy with everolimus 10 mg/day orally or placebo plus oral exemestane 25 mg/day. Patients who had received more than one prior chemotherapy regimen for advanced breast cancer were excluded from enrollment. The primary endpoint was progression free survival. Secondary endpoints included overall survival, overall response rate, incidence of adverse events, patient reported outcomes and clinical benefit rate.
Afinitor (everolimus) tablets is approved in the European Union (EU) for the treatment of patients with advanced Renal Cell Carcinoma (RCC) whose disease has progressed on or after treatment with Vascular Endothelial Growth Factor (VEGF)-targeted therapy and also in the US and in Switzerland for the treatment of patients with advanced RCC after failure of treatment with sunitinib or sorafenib.
In Switzerland, everolimus is approved with the trade name Votubia (everolimus) tablets for the treatment of patients three years of age and older with Sub-Ependymal Giant cell Astrocytoma (SEGA) associated with Tuberous Sclerosis (TS) for whom surgery is not a suitable option. Should everolimus be approved in the EU, the trade name will be Votubia. In the US, Afinitor is approved to treat patients with SEGA associated with TS who require therapeutic intervention but are not candidates for curative surgical resection. The effectiveness of everolimus is based on an analysis of change in SEGA volume. Clinical benefit such as improvement in disease-related symptoms or increase in overall survival has not been shown.
Afinitor is also approved in the US for the treatment of progressive neuroendocrine tumours of pancreatic origin in patients with unresectable, locally advanced or metastatic disease. The US Food and Drug Administration determined that the safety and effectiveness of Afinitor in the treatment of patients with carcinoid tumours have not been established. Novartis has submitted a marketing application for everolimus to the European Medicines Agency for this use, and similar regulatory submissions are under way worldwide.
In the EU, everolimus is available in different dosage strengths for the non-oncology patient population under the trade name Certican for the prevention of organ rejection in heart and kidney transplant recipients. In the US, everolimus is available in different dosage strengths under the trade name Zortress for the prophylaxis of organ rejection in adult patients at low-moderate immunologic risk receiving a kidney transplant.
Everolimus is exclusively licensed to Abbott and sub-licensed to Boston Scientific for use in drug-eluting stents.
Not all indications are available in every country. Access to everolimus outside of the approved indications has been carefully controlled and monitored in clinical trials designed to better understand the potential benefits and risks of the compound. Because of the uncertainty of clinical trials, there is no guarantee that everolimus will become commercially available for breast cancer anywhere in the world. The efficacy and safety of everolimus in breast cancer has not been established.
Novartis provides healthcare solutions that address the evolving needs of patients and societies and focused solely on healthcare, it offers a diversified portfolio to best meet these needs: innovative medicines, eye care, cost-saving generic pharmaceuticals, consumer health products, preventive vaccines and diagnostic tools.